Advertisement
News
Advertisement

Company to Attend American Academy of Dermatology's 70th Annual Meeting in San Diego, California

Thu, 03/15/2012 - 6:45am
The Associated Press

(http://www.verisante.com/)

Verisante Technology, Inc.(http://www.verisante.com/) (TSX

VENTURE:VRS)(OTCQX:VRSEF)(PINKSHEETS:VRSEF)(FRANKFURT:V3T) (the

"Company" or "Verisante"), a leader in cancer detection technology,

announced today that the Company has entered into an exclusive

agreement with Clarion Medical Technologies Inc. ("Clarion") to

distribute Verisante Aura in Canada.

"Clarion has broad and deep relationships with the leading

dermatologists and dermatology clinics across Canada and a wealth of

experience in introducing innovative technologies to the

dermatological industry," said Thomas Braun, President & CEO of

Verisante. "With a reputation for distributing superior products and

providing exceptional service, we believe Clarion is the ideal partner

to assist us in the sales, distribution, and servicing of Verisante

Aura within Canada."

Clarion has a current line of products that directly relate to UV

damage and skin care treatments, in addition to dermatological

products and devices utilizing optical technologies for a variety of

other medical applications, making Verisante Aura a natural addition

to this existing product line.

"Clinical study results have shown that Verisante Aura is a device

that has the potential to revolutionize the way skin cancer is

diagnosed," said Dan Webb, CEO of Clarion. "Clarion is very excited to

be the Aura's exclusive distributor in Canada and to be able to bring

this life-saving technology to medical professionals across the

country."

Verisante Aura is indicated for use for the evaluation of skin

lesions that may be clinically suspicious for melanoma, squamous cell

carcinoma and/or basal cell carcinoma when a medical professional

chooses to obtain additional information to rule out one of the above

conditions before making a final decision to biopsy. Aura is a

non-invasive optical system that uses Raman spectroscopy to

biochemically analyze the skin, providing immediate and accurate

results. The device will help to automate the current process of

diagnosis, allowing rapid scanning of the 20 to 40 skin lesions on

at-risk individuals, improving patient outcomes and comfort.

Verisante also announced it will have an information and education

booth at the American Academy of Dermatology conference in San Diego,

CA from March 17-19 (booth ?2825).

About Clarion Medical Technologies

Formerly known as Coherent-AMT, Clarion Medical Technologies

Inc.(http://www.clarionmedical.com/) is a medical distributor of

innovative technology solutions, operating in Canada since 1989. Over

that time, Clarion has gained a superior reputation for dedication to

the Canadian healthcare community, serving Canadian hospitals and

private practices with best-in-class products, comprehensive education

and business building programs, award winning technical support and

many more unique services.

About Verisante Technology, Inc.

Verisante is a medical device company(http://www.verisante.com/about/)

committed to commercializing innovative systems for the early

detection of cancer(http://www.verisante.com/). The Verisante Aura

for skin cancer detection(http://www.verisante.com/products/aura/) and

the Verisante Core series for lung, colon and cervical cancer

detection(http://www.verisante.com/products/core/) utilize a

proprietary cancer detection platform while the operating software and

probe technology are unique to each device. The cancer detection

platform was developed by the BC Cancer Agency and tested and refined

at the Skin Care Centre at Vancouver General Hospital. This exclusive

platform technology allows Verisante to develop and offer a range of

compact, non-invasive cancer detection devices that offer physicians

immediate results(http://www.verisante.com/products/aura/) for many of

the most common cancers. The Aura has been approved for sale in

Canada, Europe and Australia. The Core has not yet been approved for

sale.

Verisante Aura was recently awarded Popular Science Magazine's "Best

of What's New

Award(http://www.popsci.com/bown/2011/product/verisante-aura)" for

2011, and Verisante Core was named one of the top 10 cancer

breakthroughs(http://verisante.com/news/72/canadian-cancer-society-names-verisante-core-a-top-10-cancer-breakthrough-of-2011-/)

of 2011 by the Canadian Cancer Society. In addition, the Company was

named a finalist for the 2011 Regional Awards for New

Technology(http://cme-mec.ca/?actionshow&lidJCKNC-E742G-1W6JA&cid39A7P-BQXJT-NYWII&comactionshow)

by the Canadian Manufacturers & Exporters and the National Research

Council of Canada and named as the year's top ranking Technology and

Life Sciences Company on the TSX Venture

50(http://www.tmx.com/en/news_events/news/news_releases/2012/2-15-2012_TMXGroup-2012Venture50.html).

Website: www.verisante.com(http://www.verisante.com/)

Youtube: www.youtube.com/verisante(http://www.youtube.com/verisante)

Twitter: www.twitter.com/verisante(http://www.twitter.com/verisante)

Facebook:

www.facebook.com/verisante(http://www.facebook.com/verisante)

Forward Looking Statements

This release contains forward-looking statements, including, but not

limited to, statements regarding the future commercialization of

medical devices, the market demand for these products and the

proprietary protections the Company will obtain with regard to the

technology, all of which statements are subject to market risks, and

the possibility that the Company will not be able to obtain patent

protection or obtain sufficient customer demand. These statements are

made based upon current expectations and actual results may differ

from those projected due to a number of risks and uncertainties.

The TSX Venture Exchange has neither approved nor disapproved of the

contents of this press release. Neither the TSX Venture Exchange nor

its Regulation Services Provider (as that term is defined in the

policies of the TSX Venture Exchange) accepts responsibility for the

adequacy or accuracy of this press release.

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading